Skip to main content

Table 3 Responses by geographic area; p-values determined via chi-squared analysis with multiple group comparison

From: Perspectives on the COVID-19 pandemic impact on cardio-oncology: results from the COVID-19 International Collaborative Network survey

Survey Question United States Europe Latin America P-value
Yes (n (%)) No (n (%)) Yes (n (%)) No (n (%)) Yes (n (%)) No (n (%)) Statistical significance < 0.05
“Does your institution provide proper protection for all health care workers to the level they are exposed?” 759 (70.3%) 320 (29.7%) 58 (62.4%) 35 (37.6%) 104 (66.2%) 53 (33.8%) 0.168
“Have timely surgery/chemo/immunotherapy treatments for your patients been delayed since the COVID-19 pandemic started?” 565 (56.8%) 429 (432%) 44 (50%) 44 (50%) 87 (56.1%) 68 (43.9%) 0.009
“Do you use telemedicine to reduce in-person encounters and health care providers’ exposure?” 950 (88%) 129 (12%) 74 (81.3%) 17 (18.7%) 101 (63.9%) 57 (36.1%) < 0.001
“Have you been asked to reduce your specialized practice to help/contribute to other areas where urgent help is needed?” 368 (34%) 713 (66%) 61 (65.6%) 32 (34.4%) 96 (61.5%) 60 (38.5%) < 0.001
“Have you had in service instruction/guidelines from leadership at your institution about policies to protect your patients, your team, your colleagues and yourself?” 943 (86.7%) 145 (13.3%) 83 (89.2%) 10 (10.8%) 132 (84.1%) 25 (15.9%) 0.609
“Do you feel you have adequate support from your institution’s leadership to carry on with your duties?” 800 (74.1%) 279 (25.9%) 56 (60.2%) 37 (39.8%) 96 (61.9%) 59 (38.1%) 0.001
“Do you discuss with all your patients the importance of strict adherence to COVID-19 community behavior as part of your office/clinic encounters?” 978 (91.1%) 95 (8.9%) 87 (94.6%) 5 (5.4%) 152 (96.2%) 6 (3.8%) 0.035
“Do you have access to COVID-19 testing at your institution or local lab?” 812 (75%) 270 (25%) 62 (66.7%) 31 (33.3%) 84 (53.5%) 73 (46.5%) < 0.001
“Has your institution used Tocilizumab or other anti-inflammatory agents for COVID-19 related myocarditis?” 156 (16.9%) 768 (83.1%) 10 (11.6%) 76 (88.4%) 14 (9%) 141 (91%) < 0.001
Has your institution used empiric treatment with Remdesivir or other anti-viral treatments for the sickest patients? 323 (33.8%) 632 (66.2%) 18 (20.7%) 69 (79.3%) 24 (15.4%) 132 (84.6%) < 0.001
“In your opinion, should there be a government mandated nationwide quarantine/lock-down to slow down the propagation/transmission of COVID-19?” 910 (84.4%) 168 (15.6%) 84 (92.3%) 7 (7.7%) 142 (91.6%) 13 (8.4%) 0.152
“Should medical professional organizations take a more active role, and have more influence in official health care policy decisions during this major crisis?” 1035 (95.5%) 49 (4.5%) 88 (95.7%) 4 (4.3%) 147 (93.6%) 10 (6.4%) 0.765